Pereyra, D.; Rumpf, B.; Ammann, M.; Perrodin, S. F.; Tamandl, D.; Haselmann, C.; Stift, J.; Brostjan, C.; Laengle, F.; Beldi, G.; Gruenberger, T.; Starlinger, P. (2019). The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy. Annals of surgical oncology, 26(3), pp. 791-799. Springer 10.1245/s10434-018-07125-6
|
Text
Pereyra2019_Article_TheCombinationOfAPRIAndALBIFac.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (756kB) | Preview |
BACKGROUND
Neoadjuvant chemotherapy (NeoCTx) is performed for most patients with colorectal cancer liver metastases (CRCLM). However, chemotherapy-associated liver injury (CALI) has been associated with poor postoperative outcome. To date, however, no clinically applicable and noninvasive tool exists to assess CALI before liver resection.
METHODS
Routine blood parameters were assessed in 339 patients before and after completion of NeoCTx and before surgery. The study assessed the prognostic potential of the aspartate aminotransferase (AST)-to-platelet ratio index (APRI), the albumin-bilirubin grade (ALBI), and their combinations. Furthermore, an independent multi-center validation cohort (n = 161) was included to confirm the findings concerning the prediction of postoperative outcome.
RESULTS
Higher ALBI, APRI, and APRI + ALBI were found in patients with postoperative morbidity (P = 0.001, P = 0.064, P = 0.001, respectively), liver dysfunction (LD) (P = 0.009, P = 0.012, P < 0.001), or mortality (P = 0.037, P = 0.045, P = 0.016), and APRI + ALBI had the highest predictive potential for LD (area under the curve [AUC], 0.695). An increase in APRI + ALBI was observed during NeoCTx (P < 0.001). Patients with longer periods between NeoCTx and surgery showed a greater decrease in APRI + ALBI (P = 0.006) and a trend for decreased CALI at surgery. A cutoff for APRI + ALBI at - 2.46 before surgery was found to identify patients with CALI (P = 0.002) and patients at risk for a prolonged hospital stay (P = 0.001), intensive care (P < 0.001), morbidity (P < 0.001), LD (P < 0.001), and mortality (P = 0.021). Importantly, the study was able to confirm the predictive potential of APRI + ALBI for postoperative LD and mortality in a multicenter validation cohort.
CONCLUSION
Determination of APRI + ALBI before surgery enables identification of high-risk patients for liver resection. The combined score seems to dynamically reflect CALI. Thus, APRI + ALBI could be a clinically relevant tool for optimizing timing of surgery in CRCLM patients after NeoCTx.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine |
UniBE Contributor: |
Perrodin, Stéphanie Fabienne, Beldi, Guido Jakob Friedrich |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1068-9265 |
Publisher: |
Springer |
Language: |
English |
Submitter: |
Lilian Karin Smith-Wirth |
Date Deposited: |
08 Mar 2019 16:44 |
Last Modified: |
05 Dec 2022 15:26 |
Publisher DOI: |
10.1245/s10434-018-07125-6 |
PubMed ID: |
30617869 |
BORIS DOI: |
10.7892/boris.125782 |
URI: |
https://boris.unibe.ch/id/eprint/125782 |